CN107917869A - 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 - Google Patents
体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 Download PDFInfo
- Publication number
- CN107917869A CN107917869A CN201711139300.8A CN201711139300A CN107917869A CN 107917869 A CN107917869 A CN 107917869A CN 201711139300 A CN201711139300 A CN 201711139300A CN 107917869 A CN107917869 A CN 107917869A
- Authority
- CN
- China
- Prior art keywords
- body fluid
- fluid sample
- cell
- tumour cell
- fluorescence signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 131
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 54
- 239000010839 body fluid Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 36
- 208000037323 Rare tumor Diseases 0.000 title abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 90
- 230000002503 metabolic effect Effects 0.000 claims abstract description 60
- 239000003550 marker Substances 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 18
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 11
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 claims abstract 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical group C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 claims description 47
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 claims description 46
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 38
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 37
- 238000001514 detection method Methods 0.000 claims description 28
- 206010020674 Hypermetabolism Diseases 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 206010048612 Hydrothorax Diseases 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
- 238000005034 decoration Methods 0.000 claims description 8
- 238000003205 genotyping method Methods 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 abstract description 5
- 230000037149 energy metabolism Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 42
- 201000011510 cancer Diseases 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 20
- 230000001394 metastastic effect Effects 0.000 description 14
- 206010061289 metastatic neoplasm Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 10
- 230000036210 malignancy Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 230000000505 pernicious effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 102000005548 Hexokinase Human genes 0.000 description 3
- 108700040460 Hexokinases Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000025164 anoikis Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 238000012636 positron electron tomography Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- GVEBOQDOPLERMC-BGCUHRRXSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]oxane-2,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC1=CC=C([N+]([O-])=O)C2=NON=C12 GVEBOQDOPLERMC-BGCUHRRXSA-N 0.000 description 1
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- -1 hydrogen phenoxazines Chemical class 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1429—Electro-optical investigation, e.g. flow cytometers using an analyser being characterised by its signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G01N15/01—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N2015/03—Electro-optical investigation of a plurality of particles, the analyser being characterised by the optical arrangement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G01N2015/1022—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
Abstract
Description
Claims (10)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711139300.8A CN107917869B (zh) | 2017-11-16 | 2017-11-16 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
EP18879297.2A EP3712599B1 (en) | 2017-11-16 | 2018-10-24 | Method for detecting and typing rare tumor cells in body fluid sample and kit therefor |
PCT/CN2018/111546 WO2019095943A1 (zh) | 2017-11-16 | 2018-10-24 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
US16/867,177 US11047858B2 (en) | 2017-11-16 | 2020-05-05 | Method for detecting and typing rare tumor cells in body fluid sample and kit therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711139300.8A CN107917869B (zh) | 2017-11-16 | 2017-11-16 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107917869A true CN107917869A (zh) | 2018-04-17 |
CN107917869B CN107917869B (zh) | 2020-06-19 |
Family
ID=61895630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711139300.8A Active CN107917869B (zh) | 2017-11-16 | 2017-11-16 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11047858B2 (zh) |
EP (1) | EP3712599B1 (zh) |
CN (1) | CN107917869B (zh) |
WO (1) | WO2019095943A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019095943A1 (zh) * | 2017-11-16 | 2019-05-23 | 苏州浚惠生物科技有限公司 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
WO2020206891A1 (zh) * | 2019-04-10 | 2020-10-15 | 苏州浚惠生物科技有限公司 | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 |
CN112304816A (zh) * | 2020-10-28 | 2021-02-02 | 宁夏医科大学总医院 | 一种脑脊液细胞特征采集方法和装置 |
CN113567675A (zh) * | 2020-04-28 | 2021-10-29 | 苏州浚惠生物科技有限公司 | 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112147326B (zh) * | 2020-09-04 | 2022-04-08 | 北京大学 | 一种肿瘤免疫细胞亚群分型精准检测试剂盒 |
WO2024021040A1 (zh) * | 2022-07-29 | 2024-02-01 | 曾繁根 | 细胞辨识方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104122254A (zh) * | 2014-01-23 | 2014-10-29 | 贵州大学 | 一种肿瘤细胞药敏动态测定方法 |
CN105954246A (zh) * | 2016-04-29 | 2016-09-21 | 上海交通大学 | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253298A (ja) * | 2001-03-02 | 2002-09-10 | Wako Pure Chem Ind Ltd | 薬剤感受性試験の迅速判定法 |
US20030152549A1 (en) * | 2001-12-04 | 2003-08-14 | Palladino Michael A. | Methods and apparatus for cell based screening |
JP4779115B2 (ja) * | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | 早期肺癌の術後予後検査方法 |
CA2906962C (en) * | 2013-03-15 | 2022-10-11 | Anpac Bio-Medical Science (Lishui) Co., Ltd. | Methods and apparatus for enhanced detection of diseases |
WO2016044260A1 (en) * | 2014-09-15 | 2016-03-24 | Duke University | Compositions and methods for the capture and characterization of circulating tumor cells |
CN105063165B (zh) * | 2015-07-31 | 2018-12-28 | 上海交通大学 | 循环肿瘤细胞代谢活动检测方法和装置 |
CN107917869B (zh) * | 2017-11-16 | 2020-06-19 | 苏州浚惠生物科技有限公司 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
-
2017
- 2017-11-16 CN CN201711139300.8A patent/CN107917869B/zh active Active
-
2018
- 2018-10-24 EP EP18879297.2A patent/EP3712599B1/en active Active
- 2018-10-24 WO PCT/CN2018/111546 patent/WO2019095943A1/zh unknown
-
2020
- 2020-05-05 US US16/867,177 patent/US11047858B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104122254A (zh) * | 2014-01-23 | 2014-10-29 | 贵州大学 | 一种肿瘤细胞药敏动态测定方法 |
CN105954246A (zh) * | 2016-04-29 | 2016-09-21 | 上海交通大学 | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 |
Non-Patent Citations (5)
Title |
---|
ROGER G. O’NEIL ET AL.: "Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells", 《MOLECULAR IMAGING AND BIOLOGY》 * |
YIN TANG ET AL.: "High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients", 《PNAS》 * |
中国癌症基金会等: "《中国肿瘤临床年鉴》", 30 September 2017 * |
涂刚等: "《细胞能量学与量子医学——能量与健康密码》", 30 November 2012 * |
甄茹等: "刃天青法检测K562细胞对几种抗肿瘤药物的敏感性", 《山地农业生物学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019095943A1 (zh) * | 2017-11-16 | 2019-05-23 | 苏州浚惠生物科技有限公司 | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 |
US11047858B2 (en) | 2017-11-16 | 2021-06-29 | Suzhou Junhui Biotechnology Co., Ltd. | Method for detecting and typing rare tumor cells in body fluid sample and kit therefor |
WO2020206891A1 (zh) * | 2019-04-10 | 2020-10-15 | 苏州浚惠生物科技有限公司 | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 |
CN111812323A (zh) * | 2019-04-10 | 2020-10-23 | 苏州浚惠生物科技有限公司 | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 |
US11255859B2 (en) | 2019-04-10 | 2022-02-22 | Suzhou Junhui Biotechnology Co., Ltd. | Use of hexokinase-2 in detection of rare tumor cells in body fluid sample and kit |
CN111812323B (zh) * | 2019-04-10 | 2022-04-12 | 杭州浚惠生物科技有限公司 | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 |
CN113567675A (zh) * | 2020-04-28 | 2021-10-29 | 苏州浚惠生物科技有限公司 | 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒 |
CN113567675B (zh) * | 2020-04-28 | 2023-09-22 | 苏州浚惠生物科技有限公司 | 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒 |
CN112304816A (zh) * | 2020-10-28 | 2021-02-02 | 宁夏医科大学总医院 | 一种脑脊液细胞特征采集方法和装置 |
Also Published As
Publication number | Publication date |
---|---|
EP3712599A4 (en) | 2021-08-11 |
US20200264180A1 (en) | 2020-08-20 |
WO2019095943A1 (zh) | 2019-05-23 |
EP3712599A1 (en) | 2020-09-23 |
CN107917869B (zh) | 2020-06-19 |
US11047858B2 (en) | 2021-06-29 |
EP3712599B1 (en) | 2024-02-28 |
EP3712599C0 (en) | 2024-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107917869A (zh) | 体液样本中稀有肿瘤细胞的检测分型方法及其试剂盒 | |
CN105063165B (zh) | 循环肿瘤细胞代谢活动检测方法和装置 | |
CN101587043B (zh) | 从生物体液样本中富集与检测稀有细胞的整合方法 | |
CN106635995B (zh) | 一种循环肿瘤细胞阴性富集方法 | |
CN105807057B (zh) | 一种捕获和鉴定循环肿瘤细胞同步进行的方法 | |
CN105954246B (zh) | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 | |
CN104094116B (zh) | 在哺乳动物个体中检测5t4阳性循环肿瘤细胞的方法和诊断5t4阳性癌症的方法 | |
Lopresti et al. | Sensitive and easy screening for circulating tumor cells by flow cytometry | |
US20090029378A1 (en) | High sensitivity multiparameter method for rare event analysis in a biological sample | |
CN101292043A (zh) | 利用细菌噬菌体鉴定微生物的方法和装置 | |
Denes et al. | Metastasis blood test by flow cytometry: In vivo cancer spheroids and the role of hypoxia | |
He et al. | Detection of circulating tumour cells with the CellSearch system in patients with advanced-stage head and neck cancer: preliminary results | |
ES2930651T3 (es) | Métodos y composiciones para la detección citométrica de células tumorales circulantes en una muestra | |
Lei et al. | Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer | |
Fu et al. | Liquid biopsy technologies for hematological diseases | |
Liu et al. | Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B | |
CN114540491B (zh) | 一种基于岩藻糖基化细胞外囊泡中差异化表达miRNA的肝癌预测模型建立及应用 | |
CN102279264A (zh) | 48种恶性肿瘤标志物抗体芯片的制备方法 | |
Glüer et al. | Polysialylated neural cell adhesion molecule as a marker for differential diagnosis in pediatric tumors | |
Shi et al. | Lectin microarrays differentiate carcinoma cells from reactive mesothelial cells in pleural effusions | |
Oklu et al. | Relationship between hepatocellular carcinoma circulating tumor cells and tumor volume | |
Wang et al. | Clinical impact of metagenomic next-generation sequencing of peripheral blood for the diagnosis of invasive mucormycosis: a single-center retrospective study | |
CN114457139A (zh) | 细胞检测方法及试剂盒 | |
CN106990080A (zh) | 一种基于液体活检的非小细胞肺癌检测的试剂盒 | |
Kosuge et al. | Nuclear features of infiltrating urothelial carcinoma are distinguished from low-grade noninvasive papillary urothelial carcinoma by image analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190118 Address after: 215400 3rd floor, No. 52 Yingang Road, Taicang Port Economic and Technological Development Zone, Suzhou City, Jiangsu Province Applicant after: SUZHOU JUNHUI BIOTECHNOLOGY Co.,Ltd. Address before: 200240 No. 800, Dongchuan Road, Shanghai, Minhang District Applicant before: Shanghai Jiao Tong University |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 310000 China (Zhejiang) pilot Free Trade Zone, Hangzhou, Zhejiang Province Room 201, floor 2, building B, No. 688, Bin'an Road, Changhe street, Binjiang District, Hangzhou Patentee after: Hangzhou Junhui Biotechnology Co.,Ltd. Address before: 215400 3rd floor, No. 52 Yingang Road, Taicang Port Economic and Technological Development Zone, Suzhou City, Jiangsu Province Patentee before: SUZHOU JUNHUI BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection and typing method of rare tumor cells in body fluid samples and its reagent kit Effective date of registration: 20231207 Granted publication date: 20200619 Pledgee: Xiaoshan Branch of Agricultural Bank of China Ltd. Pledgor: Hangzhou Junhui Biotechnology Co.,Ltd. Registration number: Y2023980069934 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |